title: Sleep-related problems among children and adolescents with anxiety disorders.
abstract: OBJECTIVE
  The present study examined sleep-related problems (SRPs) among a large sample (n = 128) of youth with anxiety disorders (i.e., generalized, separation, and social). The frequency of eight specific SRPs was examined in relation to age, gender, type of anxiety disorder, anxiety severity, and functional impairment. The impact of pharmacological treatment (fluvoxamine versus pill placebo) in reducing SRPs also was examined.
  
  
  METHODS
  As part of a large, double-blind, randomized, controlled trial (Research Units on Pediatric Psychopharmacology Anxiety Study Group), clinician and parent reports of SRPs were examined among children and adolescents, ages 6 to 17 years, before and after treatment.
  
  
  RESULTS
  Eighty-eight percent of youth experienced at least one SRP, and a majority (55%) experienced three or more. Total SRPs were positively associated with anxiety severity and interference in family functioning. Significantly greater reductions in SRPs were found among children treated with fluvoxamine compared with placebo.
  
  
  CONCLUSIONS
  These findings indicate that SRPs are commonly associated with childhood anxiety disorders and suggest a need for the assessment of and attention to these problems in research and clinical settings.
authors.affiliation: Department of Psychiatry, Children's National Medical Center, Washington, DC 20010, USA. calfano@cnmc.org
authors.forename: Candice A
authors.initials: CA
authors.lastname: Alfano
authors.forename: Golda S
authors.initials: GS
authors.lastname: Ginsburg
authors.forename: Julie Newman
authors.initials: JN
authors.lastname: Kingery
mesh_terms: D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D001010:Anxiety, Separation / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D002648:Child; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010698:Phobic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D012893:Sleep Wake Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology
chemical_list: D014151:Anti-Anxiety Agents; D016666:Fluvoxamine